Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track NKTX with free AI briefings, catalyst countdowns, and dilution alerts.

NKTX · Nkarta, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$213.3M Cash on Hand
25.6mo Cash Runway
Follow NKTX by email Get an email when NKTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about NKTX, unsubscribe in one click. Privacy

📣 What NKTX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Fludarabine Systemic Sclerosis Phase 1/2 · NCT06733935 Recruiting
Belacabnagene Franleucel (NKX019) Lupus Nephritis Phase 1/2 · NCT06557265 Recruiting
Cyclophosphamide LD Systemic Lupus Erythematosus Phase 1 · NCT06518668 Enrolling by invitation

Also used in these trials (approved or third-party drugs, not NKTX's own candidates): Cyclophosphamide.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

NKTX holds $213.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $25M/quarter from operations, an estimated runway of 25.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 25 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NKTX files for a raise →

👥 Who Owns NKTX

Insiders 1.7% Institutions (179 holders) 83.1% Public and other holders 15.2%
HolderTypeShares% of sharesAs of
Paul J Hastings
Chief Executive Officer, Director · +1.50M options
Insider 390,247 0.54% 2026-06-18
David Shook
Chief Medical Officer, Head of Research · +117,500 options
Insider 190,955 0.27% 2025-01-15
Nadir Mahmood
President · +957,000 options
Insider 167,727 0.23% 2026-01-15
Alicia J. Hager
Chief Legal Officer · +105,000 options
Insider 146,735 0.20% 2025-01-15
Ralph Brandenberger
Chief Technical Officer · +105,000 options
Insider 124,796 0.17% 2025-01-15
Alyssa Levin
Chief Financial and Business Officer · +105,000 options
Insider 102,662 0.14% 2025-01-15
Shawn Marshall Rose
Chief Medical Officer, Head of Research · +639,000 options
Insider 70,000 0.10% 2026-01-06

Share count 71,704,404 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full NKTX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NKTX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.